Stockreport

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile [Yahoo! Finance]

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF Business Wire Thu, February 6, 2025 at 2:05 PM GMT+1 6 min read In This Article SGMO Sustained benefit demonstrated with elevated expression of alpha-galactos [Read more]